Lobe Sciences Ltd (CSE: LOBE, OTCQB: LOBEF) has announced the election of a new board of directors following its annual general meeting. Shareholders elected Dr. Frederick D. Sancilio, Dr. Harry Jacobson, and Mr. Wesley Ramjeet to the board. Additionally, Mr. Philip Young and Mr. Baxter Phillips are departing the company for new opportunities. Dr. Sancilio has been appointed Chairman of the Board and Chief Executive Officer.
Dr. Sancilio, Chairman and CEO, stated, “Although we will miss Mr. Young and Mr. Phillips, I am enthusiastic about focusing on our strategic plans to enhance shareholder value and address the needs of patients with critical unmet medical needs.”
The Company has also appointed Mr. Rick Goulburn as the fourth board member, where he will play a key role in advancing the Company’s strategic objectives. Additionally, Mr. Jeremy Wright has been named Board and Executive Advisor, offering strategic and administrative guidance.
About Lobe Sciences Ltd.
Lobe Sciences is a biopharmaceutical company dedicated to developing treatments for diseases with unmet needs. Partnering with industry leaders, the Company conducts innovative research targeting chronic cluster headache, refractive anxiety, opioid addiction, and sickle cell disease. Currently involved in Phase 1 and Phase 2 studies, Lobe Sciences plans to launch Altemia®, a medical food aimed at supporting sickle cell patients worldwide.
